This is a preview of subscription content, log in via an institution to check access.
Notes
Funding for this study was provided by Novartis Pharmaceuticals Corporation.
Reference
Friedman H, et al. Clinical Outcomes, Health Resource Use, and Cost in Patients with Early versus Late Dual or Triple Anti-Platelet Treatment for Acute Coronary Syndrome. American Journal of Cardiovascular Drugs : Jun 2013. Available from: URL: http://dx.doi.org/10.1007/s40256-013-0026-3
Rights and permissions
About this article
Cite this article
Dual or triple anti-platelet therapy in ACS?. PharmacoEcon Outcomes News 681, 5 (2013). https://doi.org/10.1007/s40274-013-0504-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0504-5